Analysts at Capital Ideas Research initiated coverage on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) in a research report issued to clients and investors on Tuesday, Analyst Ratings News reports. The firm set a “buy” rating on the stock.
Oramed Pharmaceuticals (NASDAQ:ORMP) traded up 2.69% during mid-day trading on Tuesday, hitting $8.03. The stock had a trading volume of 103,686 shares. Oramed Pharmaceuticals has a 52-week low of $3.60 and a 52-week high of $10.68. The stock’s 50-day moving average is $7.01 and its 200-day moving average is $7.27. The company’s market cap is $63.4 million.
Separately, analysts at Aegis initiated coverage on shares of Oramed Pharmaceuticals in a research note to investors on Tuesday. They set a “buy” rating and a $25.00 price target on the stock.
Oramed Pharmaceuticals Inc is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.